Evidence map›Paper›PMID 31128597›Full record

ArticleSystematic reviews2019

Mesenchymal stem cells for sensorineural hearing loss: protocol for a systematic review of preclinical studies.

Kevin T Chorath, Matthew J Willis, Nicolas Morton-Gonzaba, Walter J Humann, Alvaro Moreira

Open access · goldAbstract read
In one paragraph

Article in Systematic reviews, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Kevin T ChorathDepartment of Pediatrics, Division of Neonatology, The University of Texas Health San Antonio, 7300 Floyd Curl Dr. MC-7812, San Antonio, TX, 78229, USA.
Matthew J WillisDepartment of Pediatrics, Division of Neonatology, The University of Texas Health San Antonio, 7300 Floyd Curl Dr. MC-7812, San Antonio, TX, 78229, USA.
Nicolas Morton-GonzabaDepartment of Pediatrics, Division of Neonatology, The University of Texas Health San Antonio, 7300 Floyd Curl Dr. MC-7812, San Antonio, TX, 78229, USA.
Walter J HumannDepartment of Otolaryngology, University of Tennessee Health Science Center, Memphis, TN, USA.
Alvaro MoreiraDepartment of Pediatrics, Division of Neonatology, The University of Texas Health San Antonio, 7300 Floyd Curl Dr. MC-7812, San Antonio, TX, 78229, USA. moreiraa@uthscsa.edu.
The University of Texas Health Science Center at San Antonio · USUniversity of Tennessee Health Science Center · US

Funding

Institute for Integration of Medicine & Science: A Partnership to Improve HealthKL2TR001118 · NCATS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI CLARK, ROBERT A, DOUGHERTY, DONALD M · 2013 to 2017
$3.4M
NCATS NIH HHS KL2 TR001118
6 · The paper itself

Abstract

backgroundSensorineural hearing loss (SNHL) is the most common form of hearing impairment and is characterized by a loss of receptor hair cells and/or spiral ganglion neurons. Regenerative stem cell therapy could potentially restore normal hearing and slow the progression of hearing loss in patients. Preclinical animal studies have demonstrated that mesenchymal stem cells (MSCs) could be a promising new therapy for this condition. These findings have prompted investigators to begin human clinical trials to assess the safety and efficacy of MSCs for the treatment of SNHL. The objective of the proposed systematic review is to examine the efficacy of MSCs as a therapy for SNHL in animal models.

methodsWe will include preclinical animal studies of SNHL in which MSCs are administered, and outcomes are compared against MSC-naïve controls. The primary outcome will include audiologic tests that are routinely used in experimental studies of hearing loss, such as auditory brainstem response (ABR) and distortion product otoacoustic emissions testing (DPOAE). Secondary outcomes will include histology, microscopy, gene protein expression, and behavioral responses of animals. Electronic searches of MEDLINE via PubMed, Scopus, ScienceDirect, and Cumulative Index to Nursing and Allied Health Literature (CINAHL) will be performed. Search results will be screened independently and in duplicate. Data from eligible studies will be extracted, pooled, and analyzed using random effects models. Risk of bias and publication bias will be assessed using the Systematic Review Center for Laboratory Animal Experimentation (SYRCLE) risk of bias tool and Funnel Plots/Egger's regression tests, respectively. DISCUSSION: This systematic review will provide a summary of the efficacy of MSC therapy in animal models of SNHL, utilizing functional hearing assessment as a primary outcome. Findings from this review are important because they can elucidate research gaps that should be addressed in future preclinical studies and in turn can be translated into clinical studies. SYSTEMATIC REVIEW REGISTRATION: CAMARADES ( http://www.dcn.ed.ac.uk/camarades/ ).

Indexed as

AnimalsDisease Models, AnimalHearing Loss, SensorineuralMesenchymal Stem Cell TransplantationResearch DesignSystematic Reviews as TopicTreatment OutcomeAnimal modelsMesenchymal stem cellsPreclinicalRisk of biasSensorineural hearing lossStem cellsSystematic reviews

Identifiers

PMID31128597
PMCPMC6535185
OpenAlexW2947877370

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.